GT Biopharma (GTBP) Assets Average (2011 - 2026)

GT Biopharma (GTBP) has reported Assets Average for 15 consecutive years, with $9.1 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Assets Average rose 162.73% year-over-year to $9.1 million in Q1 2026; TTM through Mar 2026 was $9.1 million, a 162.73% increase from a year earlier, with the FY2025 full-year figure at $6.2 million, down 32.73% from the prior year.
• Assets Average was $9.1 million for Q1 2026 at GT Biopharma, up from $6.2 million in the prior quarter.
• Over five years, Assets Average peaked at $29.8 million in Q1 2022 and troughed at $3.4 million in Q1 2025.
• A 5-year average of $14.3 million and a median of $15.1 million in 2023 frame the typical range for Assets Average.
• Across the five-year window, Assets Average sank 71.32% in 2025 and jumped 162.73% in 2026, its largest moves.
• Over 5 years, Assets Average stood at $18.9 million in 2022, then fell by 19.97% to $15.1 million in 2023, then slumped by 63.67% to $5.5 million in 2024, then gained by 13.07% to $6.2 million in 2025, then surged by 45.67% to $9.1 million in 2026.
• The last three Assets Average figures came in at $9.1 million (Q1 2026), $6.2 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.